Researchers Submit Patent Application, "Combination Therapy", for Approval (USPTO 20240148733).
In: Stem Cell Week, 2024-05-30, S. 622-622
serialPeriodical
Zugriff:
A patent application has been submitted for a combination therapy that targets the YAP/TAZ-TEAD and KRAS signaling pathways in cells. This therapy, which involves administering inhibitors for both pathways, aims to treat various diseases, including cancer. The application provides background information on the role of Ras and the Hippo pathway in cancer development and highlights the potential of inhibitors to improve treatment outcomes. The patent describes a method of treating cancer by administering the combination therapy to patients with hematological cancer, pancreatic cancer, MYH-associated polyposis, colorectal cancer, or lung cancer. The therapy can be given simultaneously or sequentially, and the patent also includes a kit with the therapy and instructions for use. [Extracted from the article]
Copyright of Stem Cell Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Combination Therapy", for Approval (USPTO 20240148733).
|
---|---|
Zeitschrift: | Stem Cell Week, 2024-05-30, S. 622-622 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1537-1360 (print) |
Sonstiges: |
|